Oct 21 (Reuters) - Hoth Therapeutics Inc HOTH.O:
HOTH THERAPEUTICS REPORTS FDA ORPHAN DRUG DESIGNATION AND STRONG PRECLINICAL DATA FOR HT-KIT IN RARE C-KIT-DRIVEN CANCERS
Source text: ID:nPn4BpwJBa
Further company coverage: HOTH.O
((Reuters.Briefs@thomsonreuters.com;))